I thought I heard about a 50-50 split between Dacogen sales and Vidaza sales. If so, its amazing considering all the great press on Vidaza.
Makes me wonder, if the doctors know something the analysts don't or something the analysts glossed over?
The call was very impressive. I am a bit skeptical, based on SUPG's history.
I think it is only a question of time before the stock is discovered. I would not be disappointed, if the July 2.50 covered calls I sold expired worthless. I have stock not hedged also, but the short term return was to great for my greedy glands to buy stock and get 25% return in 3 months with little downside risk IMO.
I am really tempted to add some more, but am being a bit patient.
Why din't Supergen post an anouncement about this:
Outside of North America the sublicense of Dacogen Janssen-Cilag a Johnson and Johnson Company. Janssen-Cilag continues to actively file Dacogen and select jurisdictions where FDA approved drugs may be registered. Dacogen is now approved and marketed in Russia and other countries and we have recently become to recognize revenues from Janssen-Cilag sales and marketing efforts outside of North America.
With EU approval there is a milestone payment due of 25 million. There finance estimates are very very very conservative. There budget does not include this payment potential.
Royalty payments do not include OUS sales.
There is only upside surprise this year and next!!
There will be no EU approval this year since J&J will not even apply until later in the year after EORTC trial is announced Additionally if trial does not show a survival benifit (I doubt that it won't) J&J wont be able to apply. Since money coming in from other countries eg Russia is probably minimal they did the right thing with their guidance. Besides the street doesnt put a lot of creedence in one time payments and they like recurring earnings and growth.